Miruvor
Sign up
The short answer

What studies of triphala found

3papers on triphala
37people in 1 study testing triphala alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group and the placebo trial (very low certainty): 3 of 4 findings are C.

4 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Triphala might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 3 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Triphala · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Breathlessness1 study · 37 people took triphala Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (37 in all); effect size 0.08 (very small); the benefit is very small.

The placebo trial78 randomised · 37 analysed · 8 weeks · 1000 mg/day, five days per week for eight weeks

Breathlessness improved more than in the comparison group.

The evidence is very uncertain about the effect of triphala on breathlessness in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (37 in all)
  • Effect size 0.08 (very small)
  • The benefit is very small

How big was the difference?

0.08, very small. The effect size compares triphala with placebo.

See the 1 study
  1. Ameliorative Effects of Triphala Supplementation on Oxidative Stress and Inflammation in Individuals with Post-COVID-19 Condition: A Preliminary Randomized Controlled Trial. (2025)

    People in the study
    78 randomised · 37 analysed
    Dose
    1000 mg/day, five days per week for eight weeks
    Outcome
    respiratory symptoms (breathlessness, cough)
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    High
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Fatigue1 study · 37 people took triphala Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (37 in all).

Studies with no comparison group78 randomised · 37 analysed · 8 weeks · 1000 mg/day, five days per week for eight weeks

Fatigue improved.

The evidence is very uncertain about the effect of triphala on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (37 in all)
See the 1 study
  1. Ameliorative Effects of Triphala Supplementation on Oxidative Stress and Inflammation in Individuals with Post-COVID-19 Condition: A Preliminary Randomized Controlled Trial. (2025)

    People in the study
    78 randomised · 37 analysed
    Dose
    1000 mg/day, five days per week for eight weeks
    Outcome
    fatigue
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain1 study · 37 people took triphala Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (37 in all); effect size 0.09 (very small); the benefit is very small.

The placebo trial78 randomised · 37 analysed · 8 weeks · 1000 mg/day, five days per week for eight weeks

Pain improved more than in the comparison group.

The evidence is very uncertain about the effect of triphala on pain in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (37 in all)
  • Effect size 0.09 (very small)
  • The benefit is very small

How big was the difference?

0.09, very small. The effect size compares triphala with placebo.

See the 1 study
  1. Ameliorative Effects of Triphala Supplementation on Oxidative Stress and Inflammation in Individuals with Post-COVID-19 Condition: A Preliminary Randomized Controlled Trial. (2025)

    People in the study
    78 randomised · 37 analysed
    Dose
    1000 mg/day, five days per week for eight weeks
    Outcome
    headache
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    High
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Cognition (brain fog)1 study · 37 people took triphala Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 37 people found no clear difference; a small benefit can't be ruled out; effect size 0.01 (very small).

The placebo trial78 randomised · 37 analysed · 8 weeks · 1000 mg/day, five days per week for eight weeks

No clear difference in cognition (brain fog).

The evidence is very uncertain about the effect of triphala on cognition (brain fog) in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 37 people found no clear difference; a small benefit can't be ruled out
  • Effect size 0.01 (very small)

How big was the difference?

0.01, very small. The effect size compares triphala with placebo.

See the 1 study
  1. Ameliorative Effects of Triphala Supplementation on Oxidative Stress and Inflammation in Individuals with Post-COVID-19 Condition: A Preliminary Randomized Controlled Trial. (2025)

    People in the study
    78 randomised · 37 analysed
    Dose
    1000 mg/day, five days per week for eight weeks
    Outcome
    cognitive impairment (memory difficulties, lack of concentration)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    High
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Side effects

Stopping because of side effects2 studies

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    500 to 1000 mg at the start

  2. 2Top dose

    Most often 500 mg (1 of 2 studies)

Doses across 2 studies

500 to 1000 mg.

Each study’s dose, as printed

All papers

  1. Anti-Inflammatory and Antioxidant Effects of HIIT in Individuals with Long COVID: Insights into the Potential Role of Triphala.2025 · placebo trial · 112 randomised · 104 analysed
    Summary

    This randomized controlled trial enrolled 112 people with long COVID and post-exertional malaise; 8 did not complete the intervention (5 contracted COVID-19, 1 had unrelated health issues, 2 were unable to attend the post-intervention assessment), and 104 were included in the final analysis. Participants were allocated to a control group (no structured exercise plus placebo capsule), a HIIT group (supervised cycling HIIT three times per week for 8 weeks), or a combined group (the same HIIT plus Triphala 500 mg twice daily, totaling 1000 mg/day, for 8 weeks). The paper reports that, after the 8-week intervention, IFN-γ, TNF-α, MDA, protein carbonyls, and rating of perceived exertion showed significant reductions in both the HIIT and combined groups, with no significant differences between the two; the control group showed no significant changes for IFN-γ, TNF-α, MDA, or protein carbonyls. SOD activity increased in all groups, including the control group, with no between-group differences. Breathlessness decreased in both the HIIT and combined groups with no significant between-group difference; leg fatigue remained unchanged and comparable. No serious adverse events were reported. Minor adverse events—leg muscle fatigue, dizziness, and transient hypotension—were observed in four participants during the final week of the intervention, specifically during the fourth HIIT cycle; no participants discontinued the exercise program. The paper does not report the recruitment setting.

  2. Ameliorative Effects of Triphala Supplementation on Oxidative Stress and Inflammation in Individuals with Post-COVID-19 Condition: A Preliminary Randomized Controlled Trial.2025 · placebo trial · 78 randomised · 37 analysed
    Summary

    This preliminary randomized, double-blind, placebo-controlled trial evaluated whether Triphala changes oxidative stress, antioxidant activity and systemic inflammation in 78 people with post-COVID-19 condition in Chonburi Province, Thailand. Participants were randomly assigned to placebo (n = 38) or Triphala (1000 mg/day; n = 40), taken 5 days per week for 8 weeks; 37 in each group completed. MDA, protein carbonyl, SOD, IFN-γ and TNF-α were measured before and after supplementation. In the Triphala group, MDA (P = .026), protein carbonyl (P = .017), IFN-γ (P = .038) and TNF-α (P < .001) decreased, and SOD activity increased (P = .008); in the placebo group only SOD activity increased (P < .001). No statistically significant differences were observed between groups in any primary outcome. Mean change in protein carbonyl (0.00 vs −0.02 nmol/mg protein; P = .048) and TNF-α (−0.05 vs −0.46 pg/mL; P = .001) was significantly greater in the Triphala group. No adverse events were reported as related to either placebo or Triphala supplementation; one placebo participant (2.63%) and three Triphala participants (7.50%) withdrew due to non-compliance. The authors state that most primary outcomes did not show statistically significant between-group differences and call for larger, longer studies.

  3. The role of herbal medicine in supporting cognitive dysfunction associated with long COVID: Review2026 · review
    Summary

    This review examined herbal medicine for cognitive dysfunction associated with Post-COVID-19 Condition (PCC). The search covered PubMed, Scopus, ProQuest, and Cochrane for English-language papers with search parameters between January 2020 and November 2025; five primary clinical studies were included. These were a case study series of 5 patients given EGb761® (Ginkgo biloba); a single case of one 55-year-old female given Hochuekkito with other treatments; a prospective pilot study of 45 participants given Bojungikgi-tang, Kyungok-go, or Cheonwangbosim-dan; a retrospective cohort of 47 patients given Traditional Chinese HMs; and an RCT of 78 participants comparing Triphala with placebo. Durations varied across studies. Outcomes included cognitive severity and cognitive tests, fatigue, respiratory symptoms, emotional distress, oxidative stress, inflammatory biomarkers, and self-report questionnaires. EGb761® appeared to substantially improve cognition in all five patients, with mean time to improvement 10.6 weeks (range 7–16 weeks). The single case reported NRS reducing from 5 to 0 and BFI from 7.0 to 0.5, and TMT-A improving by 10 s. Kim et al. reported no significant between-group cognitive change (p = 0.1225), with 14 participants lost to follow-up. Hsieh et al. reported fatigue and respiratory improvements, but emotional distress changes were not significant. Intakhiao et al. found no significant between-group change in cognitive function; fatigue and headache improved in both groups, and respiratory symptoms were lower than placebo (p = 0.025). No significant adverse events were reported in the Zifko, Kim, or Intakhiao studies. Worsening or stopping was not reported. The authors state the evidence is heterogeneous and methodologically limited.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime